Introduction
Mucopolysaccharidosis I (MPS I) is an autosomal recessive lysosomal storage disease with an incidence of 1:100,000 (Baehner et al. 2005) . It is caused by deficient α-Liduronidase (IDUA; EC 3.2.1.76) activity and results in accumulation of the glycosaminoglycans (GAGs) heparan and dermatan sulfate in the lysosome (Neufeld and Muenzer 2001) . Clinical manifestations include, but are not limited to, disease of the brain, ear, eye, upper airway, bones and joints, and cardiovascular system. Severe behavioral impairment occurs in the severe form of MPS I known as Hurler syndrome (OMIM #607014). Although attenuated-severity Scheie syndrome is not classically felt to reduce behavioral function, 10 % of these patients have mild to moderate impairments in cognitive function (Thomas et al. 2010) . The etiology of behavioral dysfunction is unclear. Neurons and microglial cells accumulate GAGs, which can inhibit ganglioside-degradative lysosomal enzymes, causing accumulation of the gangliosides GM2 and GM3 (Walkley 2004) , although a causal role for these abnormalities has not been demonstrated. Increased oxidation occurs in the cerebellum (Reolon et al. 2009) .
Available treatment for patients with MPS I includes hematopoietic stem cell transplantation (HSCT) (Staba et al. 2004 ) and enzyme replacement therapy (ERT) (Kakkis et al. 2001 ). All approaches rely at least in part upon uptake of mannose 6-phosphate (M6P)-modified IDUA from the extracellular space by cells via the M6P receptor and translocation of enzyme to the lysosome. For HSCT, blood-derived cells migrate into organs, including the brain, and secrete enzymes locally, although some enzymes can be secreted into blood. HSCT has improved behavioral function in children with Hurler syndrome if performed before 2 years of age (Aldenhoven et al. 2008) . ERT involves intravenous (IV) injection of M6P-modified IDUA protein, which can be taken up by cells after diffusion from blood. Although it has been assumed that ERT would not improve behavioral function due to the blood-brain barrier, early results from a study of Hurler patients administered ERT suggests that they are developing better than expected (Wraith et al. 2007) , whereas ERT reduced abnormalities seen on magnetic resonance imaging (MRI) (Wang et al. 2009b) .
Gene therapy with gamma retroviral vectors (RV), adenoassociated virus (AAV) vectors, adenoviral vectors, lentiviral vectors, and plasmid-based vectors is being evaluated in animal models of MPS and involves transfer of a gene into cells in the body that can secrete enzyme locally or into the blood (Ponder and Haskins 2007) . Gene therapy has resulted in stable expression of IDUA in blood and reduction in lysosomal storage in the brain. However, most studies, including ours with RV, have not evaluated the effect on behavioral function. MPS I mice show multiple behavioral defects, which include reduced ambulations and rearings in an open-field test, reduced habituation to a new environment, and/or other abnormalities (Pan et al. 2008; Hartung et al. 2004; Reolon et al. 2006; Wang et al. 2009a) . Neonatal administration of an AAV vector improved habituation in the open-field test (Hartung et al. 2004) , ex vivo transduction of hematopoietic stem cells with expression in red blood cells improved habituation to a novel environment (Wang et al. 2009a) , and direct injection of an AAV8 vector into the brain improved function in a modified Morris watermaze test (Wolf et al. 2011) .
The goal of this study was to determine whether RVmediated gene therapy could improve behavioral function in MPS I mice. We previously injected RV vectors IV into MPS I mice, which demonstrated reduced lysosomal storage in the brain for some of the vectors and doses that were used (Liu et al. 2005; Ma et al. 2007; Chung et al. 2007 ). However, other vectors and doses (Metcalf et al. 2010) have not been evaluated for their effect on storage in the brain, and none of these studies have evaluated the effect on behavioral function. In this study, one vector contained a complete long-terminal repeat (LTR; LTR vector), and a second vector contained deletion in the enhancer region of the 3′ LTR that results in self-inactivation upon transduction of a cell by transferring the deletion at the 3′ end of the LTR to the 5′ end of the LTR to create the self-inactivating (SIN) vector (Metcalf et al. 2010) . The SIN vector lacks the enhancer of the LTR and is less likely to activate nearby oncogenes (Trobridge 2011) . In the study reported here, we demonstrate marked improvement in behavioral dysfunction after IV injection of the LTR vector to adult MPS I mice, as well as partial improvements after IV injection of the SIN vector to neonatal or adult MPS I mice.
Materials and methods

Reagents and vectors
All reagents were purchased from Sigma-Aldrich Chemical (St. Louis, MO, USA) unless otherwise stated. hAATcIDUA-WPRE (designated as the LTR vector here) is a gamma RV with an intact LTR at both the 5′ and 3′ ends, an extended packaging signal, the liver-specific human α 1 -antitrypsin (hAAT) promoter, the canine IDUA complementary DNA (cDNA), and the Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) (Liu et al. 2005) . SIN-hAAT-cIDUA-oPRE (designated as the SIN vector here) is a self-inactivating RV that has a deletion of the retroviral enhancer sequences in the U3 region of the 3′ LTR and lacks promoter or enhancer function at 5′ and 3′ ends of the provirus after integration (Metcalf et al. 2010) ; the oPRE is an optimized version of the WPRE, as diagramed in Supplementary Fig. 1 .
Animal care
All experiments were approved by our ethics committee, and National Institutes of Health (NIH) guidelines for the care and use of animals in research were followed. The specific mice evaluated are identical to those reported previously (Metcalf et al. 2010) . For neonatal treatment, MPS I mice on a C57BL/6 background (Ohmi et al. 2003) received IV injection of 1×10 10 transducing units (TU) per kilogram of the SIN vector at 2-3 days of age (designated hereafter as neonatal-SIN; N011), as previously described. For adult treatment, 6-week-old MPS I mice were injected intraperitoneally (IP) with hepatocyte growth factor (HGF), as detailed previously, followed by IV injection of the LTR vector (designated hereafter as adult-LTR; N010) or the SIN vector (designated hereafter as adult-SIN; N06). The cumulative dose of RV was 1.7×10 10 TU/kg for adult-LTRtreated mice and 1×10 10 TU/kg for adult-SIN-treated mice. Adult LTR-treated MPS I mice were also treated transiently with anti-CD40 ligand antibody (blocks the CD40:CD40 ligand costimulatory pathway in lymphocytes) and CTLA4-immunoglobulin (Ig) (blocks the CD80/CD86: CD28 costimulatory pathway in lymphocytes) to suppress the immune system and prevent mice from developing a cytotoxic T lymphocyte response to IDUA-expressing cells, whereas adult-SIN-treated mice did not receive immunosuppression. Phenotypically normal heterozygous mice and untreated MPS I mice from the same breeding colony were used as controls. Serum was obtained from the tail vein.
IDUA and GUSB activities
Organs were homogenized in lysis buffer at pH 5.5, as described previously (Baldo et al. 2011 ). Lysosomal-β-glucuronidase (GUSB) and IDUA assays were performed using the fluorogenic substrates 4-methylumbelliferyl-β-L-glucuronide (Sigma-Aldrich) for GUSB and 4-methylumbelliferyl-α-L-iduronide (Toronto Research Chemicals, North York, Canada) for IDUA and a FluoroSkan Ascent microplate fluorometer (Thermo Electron, Milford, MA, USA), as previously described. One unit of enzyme activity converts 1 nmol of substrate to product per hour at 37°C.
Histological analysis
Eight-month-old mice were perfused intracardially with 20 ml of phosphate-buffered saline (PBS), and brains were removed and fixed in PBS with 4 % paraformaldehyde and 2 % glutaraldehyde. Pieces of brain were embedded in plastic, and 1-μm-thick sections of cerebellum, cortex, and hippocampus were stained with toluidine blue, as described ). Neurons of the cortex and hippocampus were identified by their large nuclei and dendrites, microglial cells were identified by their small size and dark nuclei, and Purkinje cells were identified by their large size and their location at the edge of the granular layer of the cerebellum (Fuller and Burger 2007) . Sections were scored without knowledge of genotype or treatment status. Purkinje cells in the cerebellum were considered to have storage if they had two or more cytoplasmic vacuoles with GAGs when evaluated at 40× magnification. Ten fields were evaluated, and the average percentage of positive cells was determined. Neurons and microglial cells of the cortex and hippocampus were considered to have storage if they had at least three vacuoles with storage per cell. Mouse temporal bones containing the ears were fixed in the same fashion, decalcified, and embedded in paraffin, and 4-μm-thick mid modiolar sections were stained with toluidine blue.
Behavioral tests
Sensorimotor tests were performed to assess balance, strength, and coordination, as previously described (Wozniak et al. 2004 ). For screen tests, the mouse was placed on a wire mesh grid with 16 squares per 10 cm. For the vertical screen test, the screen was elevated 47 cm above the floor and inclined vertically. Each mouse was placed in the middle of the screen with its head oriented downward, and the time to climb to the top of the screen was determined. For the inverted screen test, mice were placed on top of a screen that was oriented 60°from the horizontal plane, and the screen was gently inverted until it was horizontal with the mouse upsidedown, and the time to fall off was recorded. A maximum score of 60 s was given if the mouse did not fall. For the screen tests, two trials were performed, and values for the second trial are reported. For the pole test, a mouse was placed head upward on top of a vertical rod (8 mm diameter and 55 cm tall) that had a finely textured surface, and the mouse was timed for how long it took to climb down the pole. If a mouse fell from the pole before reaching the floor, or refused to try, it was given the maximum score of 120 s. Two trials were performed, and the values for the second trial were averaged. Forelimb grip strength was evaluated with a grip strength meter (Stoelting Co., Wooddale, IL, USA), as described (Wozniak et al. 2007 ). The mouse was placed over a Perspex plate in front of a "grasping trapeze," which functions as the arm of a force transducer connected to a peak amplifier. The mouse was taught to grab the trapeze when pulled by the tail until the pulling force overcame its grip strength, and the peak pull force was measured. Each mouse received 3 days of habituation in which several trials were performed until it performed five good pulls. Testing involved two five-trial sessions, with each session being conducted on consecutive days. The mean of the pull force of the five trials performed on the second day are shown here.
Motor coordination and balance were evaluated using the rotorod test (Rotamex-5, Columbus Instruments, Columbus, OH, USA) when it was stationary, rotating at 5 revolutions per minute (rpm) for up to 60 s, and accelerating where the speed increased from 5 rpm to 20 rpm over 180 s, and the time to fall off the rod was determined (Wozniak et al. 2007 ). The Morris water-maze test was performed, as described (Wozniak et al. 2004) . During cued trials, mice were trained to swim to a submerged platform marked with visual cues; they received four trials per day for 2 consecutive days. Place trials, which are shown in the supplementary material, were also performed to test the ability of a mouse to learn the position of a platform. General locomotor activity was quantified using a computerized photobeam system (MotorMonitor, Hamilton-Kinder, LLC, Poway, CA, USA), according to previously published methods (Wozniak et al. 2004 ). The number of ambulations (whole-body movements) and vertical rearings made over 12 separate 5-min blocks or for the entire hour were recorded. In addition, walking initiation, ledge, and platform tests were performed, as described previously, and are shown in the supplementary material.
Statistics
Analysis of variance (ANOVA) with Tukey post hoc analysis or Student's t test compared values in different groups using Sigma Stat software version 3.1 (Systat Software, Inc., Point Richmond, CA, USA). If the normality and equal variance parameters of ANOVA failed, ANOVA on ranks was used to test for significance, as per program recommendation. The chi-square test determined whether the frequency of an event differed between groups.
Results
Gene transfer and brain enzyme activity
The goal of this study was to evaluate the effect of gene transfer to neonatal or adult (1.5-month-old) MPS I mice on behavioral function at 8 months of age. All mice evaluated here were previously described in terms of their transduction, but the effect on lysosomal storage in the brain and behavioral function was not reported. Adult-LTR mice were treated at 6 weeks of age with transient administration of HGF to induce the hepatocyte replication needed for transduction with this vector in adults, followed by a cumulative dose of 1.7×10 10 TU/kg of the LTR vector (Metcalf et al. 2010) , which was 1.7-fold the dose given in our initial study with this vector in adult mice ). Mice achieved stable expression of IDUA activity in serum with a mean average lifetime activity of 235±20 U/ml, as shown in Fig. 1a , which was 84-fold the value of 2.8±0.1 U/ml in homozygous normal mice and 1,175-fold the value of 0.2± 0.01 U/ml in untreated MPS I mice. A different cohort of MPS I mice was treated with the SIN vector (Metcalf et al. 2010) . Some received neonatal IV injection of 1×10 10 TU/ kg (neonatal-SIN), whereas others received IV injection of HGF at 6 weeks of age to induce hepatocyte replication, followed by 1×10 10 TU/kg (adult-SIN). Neonatal-SIN and adult-SIN mice achieved serum IDUA activity of 127± 10 U/ml (45-fold normal) and 71±7 U/ml (25-fold normal), respectively, as shown in Fig. 1a .
Brain IDUA activity is shown in Fig. 1b , which was studied from samples collected after perfusion of mice with saline to remove enzymes from blood. Adult-LTR mice achieved 5±6 U/mg of IDUA activity in the front half of the brain, which was 73 % normal (7±2 U/mg) and 96-fold the level of that in untreated MPS I mice (p00.05 for adult-LTR vs. MPS I), although there was marked variation in individual mice. It is possible that some treated animals had poor perfusion prior to tissue collection and were contaminated with IDUA from blood. Average IDUA levels in the forebrain from neonatal-SIN and adult-SIN were 0.3± 0.2 U/mg (4 % normal) and 1.4±1.1 U/mg (20 % normal), respectively, which were 5-fold and 19-fold, respectively, the 10 TU/kg of the self-inactivating version of the RV designated self-inactivating (SIN)-hAAT-cIDUA-oPRE at 2-3 days after birth (neonatal-SIN), or with 1×10 10 TU/kg of the SIN vector at 1.5 months of age (adult-SIN). Serum IDUA ± standard deviation (SD) was measured using a fluorogenic substrate, as described in the "Methods", from 1 week to 8 months of age. Results represent the average of the lifetime average for the indicated number of mice in each group. b. Forebrain and cerebellar IDUA activity. Animals were sacrificed at 8 months and IDUA levels measured in the forebrain and cerebellum for five normal, six untreated MPS I and four neonatal-SIN and three adult-SIN mice, and from forebrain of six adult-LTR mice; some treated mice were not evaluated due to lack of sample availability. The number of mice of each gender was similar. c. β-glucuronidase (GUSB) activity. The X over the position of the cerebellum data for adult-LTR-treated mice indicates that those samples were not collected and thus could not be assayed. * Represents a p value of 0.01-0.05; ** indicates a p value <0.01 for the indicated groups compared with MPS I mice using analysis of variance (ANOVA) with Tukey post hoc analysis for samples for which the normality and equal variance tests passed, and with ANOVA on ranks if these tests did not pass values for untreated mice (0.05±0.03 U/mg), although none of these differences were significant. Cerebellum IDUA activity in neonatal-SIN and adult-SIN mice were 1.8-and 3.1-fold the values in untreated MPS I mice, respectively (2 % and 4 % normal), and did not reach significance. IDUA levels were not analyzed in the cerebellum of adult-LTR mice due to the failure to collect samples.
GUSB activity was also evaluated, as other lysosomal enzymes are usually elevated in MPS I, and normalization of activity is a good biochemical indicator of correction of disease (Baldo et al. 2011 ). Adult-LTR-treated mice had 55 ±19 U/mg of GUSB activity in their forebrain, which was significantly lower than the value of 127±62 U/mg in untreated MPS I mice, but appeared to be slightly higher than the value of 31±3 U/mg in normal mice. Neonatal-SIN-and adult-SIN-treated MPS I mice did not have significant reductions in forebrain GUSB activity compared with untreated MPS I mice but did have a significant reduction in cerebellar GUSB activity, with values of 56±13 and 47±14, respectively, whereas untreated MPS I mice had 98±31 U/ mg and normal mice had 40±6 U/mg. GAG levels were not evaluated in treated mice, as our prior studies failed to identify elevations in untreated MPS I mice.
Histopathological analysis of brain
Histopathological analysis was performed to determine whether neurons and microglial cells had a reduction in accumulation of lysosomal storage material, as shown for representative examples in Supplemental Fig. 2 and as quantified in Fig. 2 . In untreated MPS I mice, 44±13 % of Purkinje cells had two or more vacuoles, which was higher than the value of 4±3 % of cells in normal mice (p<0.01).
Adult-LTR-treated mice had storage in 7±7 % of cells (p<0.01 vs. MPS I), whereas neonatal-SIN and adult-SIN mice were partially corrected, with storage in 23±12 % and 18±6 % of cells, respectively (p<0.01 vs. MPS I mice; p00.02 for neonatal-SIN vs. normal). In addition, the number of vacuoles per positive cell and the size of the vacuoles appeared to be greater in the untreated MPS I mice than in the treated mice, although this was not evaluated quantitatively.
In the cortex, MPS I mice had three or more vacuoles in 25±5 % of neurons and 45±8 % of microglial cells, which was higher than the values of 2±1 % and 2±2 % in normal mice, respectively (p<0.01 in both cases). Adult-LTR treated mice had marked reductions in the percentage of cells with three or more vacuoles for both cell types (p<0.01 vs. MPS I), whereas neonatal-SIN-and adult-SIN-treated mice had partial reductions (p<0.01 vs. MPS I). A similar pattern was seen in the hippocampus, where the percentage of cells with three or more vacuoles was elevated in untreated MPS I mice, and treated mice had statistically significant reductions.
Effect of MPS I on behavioral function
A battery of tests was performed to evaluate 8-month-old MPS I mice for behavioral abnormalities. As adult-LTRtreated MPS I mice were evaluated at a different time from the neonatal-SIN-and the adult-SIN-treated mice, behavioral tests are shown separately for these cohorts. MPS I mice performed similarly to normal controls in the time taken to climb to the top of a vertically oriented screen, suggesting that their general coordination and strength were relatively intact (Fig. 3a) . However, MPS I mice could not hold on to an inverted screen for the entire 60-s trial, as 100 % fell off when the screen was inverted so that the mouse was hanging Fig. 2 Histochemical analysis for lysosomal storage in the brain. Normal mice, untreated mucopolysaccharidosis I (MPS I) mice, or MPS I mice that were treated as detailed in Fig. 1 were sacrificed at 8 months of age. Brains were fixed, embedded in plastic, and 1-μm thick sections were stained with toluidine blue, as shown for representative samples in Supplementary Fig. 2 . The percentage of Purkinje cells in the cerebellum with two or more vacuoles thought to be lysosomal storage was determined, as detailed in "Methods." For neurons and microglial cells of the cortex and hippocampus, the percentage of cells with three or more granules thought to represent lysosomal storage was determined. Histology was evaluated for most parts of the brain from four normal, five untreated MPS I, four adultlong-terminal-repeat (LTR)-treated, four neonatal-self-inactivating (SIN)-treated, and four adult-SIN-treated MPS I mice. Gender distribution was similar. For the hippocampus, the number evaluated was three, three, four, two, and two, respectively, as some sections did not have adequate regions of this somewhat difficult-to-obtain region. ** Indicates that values were statistically significant for a particular group compared with those in untreated MPS I mice, with a p<0.01 using analysis of variance (ANOVA) and Tukey post hoc analysis upside-down, although only 13 % of normal mice fell off (p <0.001 with chi-square test). For adult-LTR-treated MPS I mice, only 20 % fell off the inverted screen, a significantly lower rate than the value in MPS I mice (p<0.001), but was not different from the value in normal mice (Fig. 3b) . In addition, the average time that MPS I mice held onto the inverted screen was very short, at 23±17 s (Fig. 3c) . In contrast, normal mice held for 57±7 s (p<0.01 vs. MPS I), which was very close to 60 s, the maximum duration of the trial. Adult-LTR-treated mice stayed on the screen for 56 ±9 s, which was significantly longer (p<0.01) than for untreated MPS I mice but was not different from the value in normal mice.
Mice were also evaluated for their ability to climb down a pole (Fig. 3d, e ), which is a task that requires strength, coordination, and vestibular function. For MPS I mice, 70 % fell off the pole, and the average time to climb down was long, at 96±41 s; any animal that fell or refused to try Fig. 3 Behavioral tests in adult-long-terminal-repeat (LTR) mice. Some mucopolysaccharidosis I (MPS I) mice with treated with intravenous (IV) injection of the LTR-intact retroviral vectors (RV) at 1.5 months of age, as described in Fig. 1 (adult-LTR) whereas other MPS I and phenotypically normal heterozygous littermates were not treated. a Behavioral tests were performed for the total number of mice indicated inside the bar , as detailed in "Methods," at 8 months of age for normal mice (four females and six males), untreated MPS I mice (five females and five males), and adult-LTR MPS I mice (five females and five males). a Vertical screen. The average time in seconds ± standard deviation (SD) to climb to the top of a vertical screen was determined. b, c. Inverted screen test. b Percentage of mice that fell off an inverted screen and c average time that mice held on to the inverted screen was determined. For the latter panel, the trial was terminated after 60 s. Analysis for the significance of event frequency between two groups was determined with chi-squared test, and analysis of variance (ANOVA) with Tukey post hoc analysis was performed to compare values in c. d-e. Vertical pole test. The percentage of mice that fell off a vertical pole and the time to climb down the vertical pole were determined as described for b and c. f Forelimb grip strength. The mean of the pull force at which mice in each group released a trapeze was determined. g Swim speed. The average swim speed in the cued trials of the Morris water maze test was determined for eight trials over 2 days. h Rearing. The number of rearings per hour when placed into a novel environment was determined. i Ambulations. The number of ambulations over 5 min was determined for 12 consecutive intervals over an hour. * and ** indicate that there were significant differences between the indicated group and untreated MPS I mice with p00.01 to 0.05 and p<0.01, respectively. Statistical analysis of i is discussed in the text was considered to take 120 s to climb down. For phenotypically normal heterozygous normal mice, 13 % fell off (p0 0.004 vs. MPS I), and took only 33±36 s to climb down the pole (p00.005 vs. MPS I). For adult-LTR-treated mice, only 10 % fell off (p00.02 vs. MPS I; not significant vs. normal), and they took 38±37 s to climb down (p00.006 vs. MPS I, not significant vs. normal). It is unlikely that the MPS I mice were weak, as their forelimb grip strength was normal (Fig. 3f) . MPS I mice did have slightly reduced swimming speeds in the Morris water maze test (Fig. 3g) , although spatial learning and memory capabilities were not found to be impaired (Supplemental Fig. 4) . Swim speed improved with adult-LTR treatment.
Activity evaluation
During the 1-h locomotion test, untreated MPS I mice exhibited 168±81 rearings, which represented a 51 % reduction relative to normal mice (341±106; p00.007), as shown in Fig. 3h . The number of rearings in adult-LTRtreated MPS I mice was at an intermediate level (232±134; 68 % normal), although values were not significantly different from those in either normal or untreated MPS I mice. The MPS I mice also showed greatly attenuated ambulatory response to initially being placed in a novel environment. Specifically, untreated MPS I mice showed reduced activity during the first 5 min (126±64 ambulations), which was 56 % of normal (p00.005). In contrast, RV-treated MPS I mice exhibited normal levels of ambulatory activity during the first 5 min of the session (232±112; 102 % normal; p0 0.002 vs. MPS I, not significant vs. normal). In addition, the number of ambulations did not change much over the 1-h test session in untreated MPS I mice, as the value in the last 5-min block was 81 % of that found in the first 5-min block (not significant for comparison of the initial and late values with the Students t test); ambulations at the end of the hour in normal mice fell to 51 % of the initial value (p0 0.001) and those in RV-treated mice to 50 % of the initial value (p <0.001). Thus, MPS I mice showed a blunted ambulatory response to novelty and did not show the typical decrease in activity across the test session indicative of habituation; adult-LTR-treated mice were normalized in both of these parameters. Values did not differ between normal, untreated MPS I, and adult-LTR-treated MPS I mice for the rotorod test (Supplemental Fig. 4 ), time to initiate walking, time spent on a ledge, and time spent on a platform (Supplemental Fig. 5 ).
Behavioral studies in neonatal-SIN-and adult-SIN-treated MPS I mice
Behavioral studies were also performed in neonatal-SINand adult-SIN-treated MPS I mice, along with a separate cohort of heterozygous normal and untreated MPS I mice, as shown in Fig. 4 . Reduced ability to hold onto an inverted screen, reduced ability to climb down a pole, reduced swim speed, reduced rearing, reduced initial activity in a novel environment, and reduced habituation to the novel environment were similar to that depicted in Fig. 3 . The only test where performance differed from that shown in Fig. 3 was the grip-strength test, where the MPS I mice had a grip strength of 34±6 g, which was lower than the value of 42 ±6 g in normal mice (71 % of normal, p<0.001 for MPS I vs. normal). The reason for the latter discrepancy is unclear, as age and gender composition of normal and untreated MPS I mice in the two studies were similar. Ambulatory activity during the first 5 min of the 1-h locomotor activity test in MPS I mice was 50 % of normal levels (p00.007 for MPS I vs. normal), which resembles the result found in the MPS I mice in Fig. 3 . MPS I mice did not exhibit habituation of ambulatory activity, as levels during the last 5 min were not significantly different from those observed in the first 5 min [105 ambulations in the first 5 min and 73 in the last 5 min, for a 30 % reduction with time (p00.10)]. In contrast, normal mice exhibited robust habituation of ambulatory activity across the test session (209 vs. 121 ambulations during the first and last 5-min blocks), for a 42 % reduction (p00.002).
Neonatal-SIN-treated mice demonstrated a significant reduction in the percent that fell off the vertical pole (p0 0.003 vs. MPS I), a reduction in the time to crawl down the vertical pole (p00.002 vs. MPS I), increase in forelimb grip strength (p<0.001 vs. MPS I), and increased numbers of ambulations in the first 5-min block in the 1-h locomotor activity test (p00.05) relative to untreated MPS I mice; however, they showed no improvements in their ability to hold on to an inverted pole, swim speeds, or the number of rearings relative to MPS I mice. In addition, the number of ambulations in the last 5-min time block of the 1-h locomotion test were only reduced by 37 %, which was not a significant difference from the number of ambulations in the first 5-min block (p00.15). Adult-SIN-treated mice had greater numbers of ambulations in the first 5-min block of the activity test compared with untreated MPS I mice (p0 0.007 vs. MPS I) and showed habituation, with a 48 % reduction in movement from the first to the last 5-min blocks mice (p00.009), but showed no improvements in other tests.
Histopathological evaluation of the middle and inner ear
As the reduced ability of MPS I mice to climb down a pole and hold on to an inverted screen could reflect reduced vestibular function, ears were evaluated for histopathological abnormalities of the vestibular system. Another reason for evaluating the ear is that we previously demonstrated that hearing was abnormal in MPS I mice and was partially improved with adult-LTR therapy (Metcalf et al. 2010) . We therefore wanted to determine the histopathological explanation for this improvement. The stapes is one of the three ossicles of the middle ear, and its footplate attaches to the wall of the vestibule via the annular ligament to form the oval window that separates the middle from the inner ear. Sound waves cause the footplate of the stapes to move, which results in a fluid wave in the inner ear that is detected by sensory cells in the cochlea. Figure 5 shows histopathology of the stapes where it attaches via the annular ligament to the bony wall of the vestibule of the inner ear. In the MPS I mouse, the ligament shows a great deal of lysosomal storage material that appears as white vacuoles (Fig. 5f ), which may be a factor in the reduced hearing. The ligaments of two adult-LTR-treated mice looked normal. All animals had some degree of exudate surrounding the stapes, which is abnormal and is consistent with a middle ear infection.
The round window membrane is the second region in which the boundary between the inner and the middle ear is not bone. Proper compliance of the round window membrane is necessary for the stapes to generate a fluid wave within the inner ear. Figure 6a , e, i show that the round window membrane is thin in a normal mouse and that the surrounding space (the antrum) is clear. In contrast, the round window membrane of an MPS I mouse is markedly thickened and contains white vacuoles with lysosomal storage material (Fig. 6j) ; the round window antrum appears full of exudative material (Fig. 6b, f) . We do not believe differences in the plane of sectioning can account for apparent differences in the thickness of the round window membrane, as Fig. 6a-d show that sectioning planes are similar for the same ears, as demonstrated by the fact that all samples have four organs of Corti within the cochlea at similar locations. Both the thickness of the round window membrane and the exudate in the adjacent antrum may reduce compliance of the round window membrane and contribute to hearing loss. The round window membrane of two adult-LTR-treated mice was less thickened than that of the MPS I mouse, but the middle ear still contained substantial exudate, as shown in Fig. 6c-d and g-k. Fig. 4 Behavior tests in neonatal-self-inactivating (SIN) and adult-SIN mice. Mucopolysaccharidosis I (MPS I) mice were injected with the SIN vector as newborns (neo-SIN) or adults (adult-SIN), as detailed in Fig. 1 , whereas phenotypically normal heterozygous and untreated MPS I littermates served as controls. Behavioral tests were performed for the total number of mice indicated inside the bar in Fig. 1a , as detailed in "Methods," at 8 months of age for normal mice (six females and seven males), untreated MPS I mice (11 females and ten males), neonatal-SIN MPS I mice (five females and six males), and adult-longterminal-repeat (LTR) MPS I mice (three females and three males), as detailed in Fig. 3 The semicircular canals contain ampullar cristae with hair cells, which are mechanoreceptor cells that sense rotation. Cristae appear as cone-shaped structures identified with arrows in the low-and middle-power views in Fig. 6a-d , and e-h, respectively. In the high-power image shown in Fig. 6n of the MPS I mouse, hair cells and surrounding support cells contain large amounts of lysosomal storage material that is absent in the normal mouse in Fig. 6m . These defects are consistent with the hypothesis that abnormal vestibular function could contribute to sensorimotor abnormalities. The adult-LTR-treated mouse with the lowest expression of the group had a partial reduction in lysosomal storage material in the cristae (Fig. 6o) , whereas an adult-LTR-treated mouse with higher expression had complete resolution of lysosomal storage (Fig. 6p) .
Discussion
Behavioral impairment is an important feature of MPS I in human patients. We previously demonstrated that neonatal-LTR-treated (Chung et al. 2007 ) and adult-LTR-treated ) MPS I mice that received 1×10 10 TU/kg of vector had reduced lysosomal storage in neurons and microglial brain cells but we had not previously evaluated brains for storage in adult-LTR mice that received a higher dosage (1.7×10 10 TU/kg) of the LTR vector or in neonatal-SIN or adult-SIN mice that received 1×10 10 TU/kg of the SIN vector. In addition, although hearing and visual tests were performed previously for all of these groups of mice, we had not previously tested behavioral function. These studies evaluated the latter three groups of treated mice mentioned above but did not evaluate the former two groups, as behavioral tests were not set up when they were sacrificed.
All mice evaluated here had stable serum IDUA activity from 1 week after transduction until the end of the study at 8 months, as shown previously for the identical mice studied here that received the SIN vector (Metcalf et al. 2010) , and as shown for a different cohort of adult-LTR mice that received a slightly lower dose of vector ). A few mice lost expression over time, presumably due to an immune response, and all such mice were excluded from Fig. 5 Histopathology of the stapes of the middle ear. Ears were collected at 8 months of age from normal, untreated mucopolysaccharidosis I (MPS I), or MPS I mice that were treated with the long-terminal-repeat (LTR) vector at 1.5 months of age (adult-LTR) and processed as detailed in "Methods." Sections from mice of the indicated groups were stained with toluidine blue. For adult-LTR mice, the average serum α-L-iduronidase (IDUA) activity for the specific animals shown is indicated. a-d. Stapes. Low-power view of the stapes where it articulates with the cochlear capsule via the annular ligament at the oval window. Arrows indicate margins of the stapes footplate. e-h. Annular ligament. The annular ligament has large amounts of lysosomal storage that appear as white bubbles (white arrow) in untreated MPS I mice; there is also storage in the chondrocytes of the articular cartilage. No storage is visible in normal or treated mice. Size markers are indicated in the panels. Results shown are representative for six normal mice, four untreated MPS I mice, and four adult-LTR-treated mice this study. Adult-LTR-, neonatal-SIN-, and adult-SINtreated MPS I mice achieved an average lifetime serum IDUA activity of 235±20 (84-fold normal), 127±10 (45-fold normal), and 71±7 U/ml (25-fold normal), respectively, although serum enzyme does not necessarily mean that enzyme will diffuse to all tissues. In general, adult-LTR mice had higher brain IDUA activity, lower levels of another lysosomal enzyme (GUSB; such a reduction is a biochemical marker of Fig. 6 Histopathological analysis of the cochlea, round window, and cristae. Mice were treated as detailed in Fig. 3 , and ears were collected at 8 months of age, processed, sectioned, and stained with toluidine blue. a-d Low-power cochlear images. The asterisk indicates the inner ear and arrows a crista of one semicircular canal. The box indicates the region shown at higher power in panels e-h with some rotation. eh Intermediate power views of the inner ear, round window membrane, and round window antrum. The asterisk indicates the inner ear, and the box indicates the region with the round window membrane shown at higher power in panels i-l. The middle ear is located to the right of the round window membrane in all panels. The antrum is clear in the normal mouse (e) but is filled with exudate in the other panels. The arrow indicates crista of one semicircular canal. i-l. Round window membrane. The asterisk indicates the inner ear, and the arrow indicates lysosomal storage material in the round window membrane in the untreated mucopolysaccharidosis I (MPS I) mouse. m-p. High-power view of crista. The black arrow in the untreated MPS I mouse shown in n indicates lysosomal storage material, which is present in crista hair and accessory cells. The adult long-terminal-repeat (LTR)-treated mouse shown in o also has lysosomal storage, although the adult-LTR-treated mouse in p does not have detectable storage. Size markers are indicated in the panels. Results shown are representative for six normal mice, four untreated MPS I mice, and four adult-LTR-treated mice disease correction), and a lower percentage of cells in the brain with lysosomal storage material than did neonatal-SIN-and adult-SIN-treated mice, which correlated with greater improvements in behavioral tests in the adult-LTR group, as will be expanded on below. The finding that adult-SIN mice had slightly higher forebrain IDUA activity than did neonatal-SIN mice is discrepant with the fact that adult-SIN mice had slightly lower serum IDUA, similar brain GUSB activity, and slightly worse performance on some behavioral tests than did neonatal-SIN mice. We believe that the brain IDUA assay is the least reliable test due to difficulties in consistently removing all blood from the brain with perfusion, whereas behavioral tests sometimes require larger numbers of animals to achieve statistical significance if differences are modest. Although it has been reported than the blood-brain barrier is more permissive to enzymes in the neonatal period (Vogler et al. 2005) , the greater efficacy of adult-LTR treatment than neonatal-SIN treatment likely reflects the fact that reductions in lysosomal storage observed at 8 months of age are due to enzymes than reached the brain during adulthood rather than during the newborn period. Treated mice were not evaluated for anti-canine IDUA antibodies in this study, but such antibodies were absent in a previous study after adult gene transfer ).
Vestibular function
In this study, MPS I mice had many behavioral abnormalities. This is the first report that MPS I mice have a profoundly reduced ability to hold on to an inverted screen and to climb down a pole. As these mice behaved normally in both the constant speed and accelerating rotorod tests (Supplemental Fig. 4) , could readily climb to the top of a vertical screen (Figs. 3a and 4a) , and had a normal grip strength in one of the two studies performed (Fig. 3f) , we infer that their cerebellar and motor functions were relatively well maintained. Nevertheless, as grip strength was abnormal in the second study (Fig. 4f) , swim speed and rearings were consistently reduced, and MPS I mice have abnormal joint histology (GB and RG, unpublished data), we cannot rule out the possibility that musculoskeletal abnormalities contributed to reduced function in these tests. We favor the hypothesis that abnormal vestibular function contributes to reduced ability to hold on to an inverted screen and climb down a pole, as we demonstrate here that MPS I mice have enormous amounts of lysosomal storage material in the hair and accessory cells of the cristae ampullaris of the semicircular canals, which are critical for sensing their position in space. Similar histochemical abnormalities were observed in cristae of MPS VII (Ohlemiller et al. 2002) and MPS IIIB (Heldermon et al. 2007 ) mice, although no functional abnormality was associated with this finding. It is unclear whether humans have abnormalities in tests that might correlate with those observed here in mice.
Adult-LTR-treated mice showed an improved ability to hold onto an inverted screen and climb down a pole compared with untreated MPS I mice. The reduction in lysosomal storage in the cristae of the semicircular canals of the inner ear in adult-LTR-treated mice may have contributed to their improved function on these tests, although improvements in bone and joint disease or muscle strength could play a role. The neonatal-SIN-and adult-SIN-treated mice did not have statistically significant improvements in performance on the inverted screen, although the neonatal-SINtreated mice had improvements in their ability to climb down a pole and in grip strength compared with untreated MPS I mice. The failure to correct the inverted screen performance may reflect the lower serum IDUA activity achieved for both SIN groups compared with adult-LTRtreated mice. Ears were not evaluated histopathologically in either of the SIN groups due to the time involved in sectioning through an entire ear.
Locomotor activity
This paper confirms the consistent report of others that the number of rearings is reduced, the initial activity in a novel environment is lower, and activity fails to decline with habituation to an environment in MPS I compared with normal mice (Reolon et al. 2006; Pan et al. 2008 ). This study failed to identify significant differences in time and path length to reach a platform in both cued and place trials between normal and MPS I mice in the Morris water maze test for the first cohort of mice that were evaluated (Supplemental Fig. 3 ), although swimming speed was reduced tõ 80 % of that in normal mice, as noted above. Some (Wolf et al. 2011) but not others (Pan et al. 2008) have reported differences at older ages in the Morris water maze test, although in these studies, time to reach the platform was reported and swim speed was not commented upon, raising the possibility that slow swimming was a factor. This study also failed to identify abnormalities in the rotorod test (Supplemental Fig. 4 ) and in other sensorimotor and locomotor tests (Supplemental Fig. 5) .
In this study, adult-LTR-treated mice did not have statistically significant improvement in the number of rearings, although there appeared to be partial improvement. Adult-LTR-treated mice did have significant improvement in their initial activity in a novel environment and habituation over time, suggesting that treatment normalized their ambulatory response to a novel environment and subsequent habituation in activity. Neonatal-SIN-and adult-SIN-treated mice did not have improvement in the number of rearings, although both had increased activity in the first 5-min block in a novel environment compared with untreated MPS I mice. The adult-SIN-treated mice showed habituation over time, whereas the neonatal-SIN mice showed no significant habituation, although the activity for this latter group in the last 5-min block of an hour-long test session was reduced by 37 % relative to the activity in the first 5 min, which was marginally nonsignificant (p00.15). Altogether, these data suggest that neonatal-SIN and adult-SIN gene therapy was less effective than adult-LTR gene therapy, which likely reflects the lower serum IDUA activity achieved with the SIN vector compared with the LTR vector. However, the SIN vector did result in some behavioral improvements.
Histochemical evaluation of the ear Schachern et al. (2007) previously reported that reduced hearing in MPS I mice was associated with a middle ear exudate at 2 months or older, that modest amounts of lysosomal storage were present in fibrocytes of the spiral ligament and mesothelial cells of the basilar and Reissner's membranes, and that there was a reduction in the number of hair cells of the cochlea at 1 year or older. We previously demonstrated that hearing was improved, but not normalized, in the same adult-LTR-treated MPS I mice that were evaluated here relative to untreated MPS I mice, as MPS I mice require 89±2 decibels (db) of sound at 10 kHz to evoke a brainstem response, and the same adult-LTRtreated mice whose ears were evaluated here only required 59±2 db, although this remained higher than the value in normal mice (39±6 db) (Metcalf et al. 2010) . Here, we report that lysosomal storage was markedly reduced in the annular ligament and was reduced, but not eliminated, in the round window membrane, which could contribute to improved hearing. However, a middle ear exudate was still consistently present in adult-LTR-treated mice, and we hypothesize that the failure to prevent an exudate with gene therapy may be a factor in the hearing deficit that persists in the adult-LTR-treated MPS I mice. A middle ear infiltrate has also been reported in MPS VII (Ohlemiller et al. 2002) and MPS IIIB (Heldermon et al. 2007 ) mice, whereas modest amounts of lysosomal storage were found in the chondrocytes in the articular cartilage of the stapes in MPS IIIB mice.
Mechanism of improvement in behavioral function
These data suggest a beneficial effect of adult-LTR gene therapy on biochemical, histopathological, and functional abnormalities in the brain of MPS I mice, and partial improvement in some parameters in neonatal-SIN-and adult-SIN-treated mice. As we were previously unable to detect RNA in the brain (Metcalf et al. 2010 ) of the same mice that were evaluated here, we believe that improvements in behavioral function likely reflect diffusion of enzymes from blood into the brain. This contradicts the dogma that enzymes cannot cross the blood-brain barrier, although the barrier is not absolute (Banks 2004) , and there is some evidence that it is disrupted in MPS IIIB (Garbuzova-Davis et al. 2011 ) and other evidence that GUSB in serum can traverse the barrier and reach the brain (Vogler et al. 2005 , Grubb et al. 2008 ). The SIN vector was less effective in this study than was the LTR vector, which likely reflects the lower expression observed in vivo, as discussed previously (Metcalf et al. 2010) . Thus, although SIN vectors are generally safer in vivo than LTR-intact vectors due to their inability to enhance expression of a nearby oncogene (Trobridge 2011) , their reduced efficacy in our hands poses a problem, and a more detailed risk-benefit analysis will need to be done to decide which vector to use. It remains possible that a better effect could be observed with the SIN vector if higher doses were used.
Other vectors have exhibited a beneficial effect on behavioral tests or would be predicted to do so. Administration of a Sleeping Beauty Transposon resulted in 1,300 U/ml (Aronovich et al. 2009 ) and a minicircle DNA resulted in 1,000 U/ml (Osborne et al. 2011) , both of which would be predicted to result in a marked behavioral improvement. Achieving IDUA levels of~100 U/ml in serum from red blood cells after transduction of hematopoietic stem cells with a lentiviral vector (Wang et al. 2009a ) improved habituation to a novel environment and increased grooming, which is a level where we also found some level of habituation to a novel environment, although the test that we performed was different. The fact that neonatal AAV2 injection that resulted in~10 U/ml in plasma at late times improved habituation (Hartung et al. 2004 ) was surprising, but expression might have been substantially higher in the newborn period, as copies of episomal AAV vectors generally decline with animal growth, and the test the authors performed was different from ours. Systemic administration of a lentiviral vector resulted in relatively low organ enzyme activity, and behavioral testing was not done (Di Domenico et al. 2006) . Ex vivo hematopoietic stem-cell-directed gene therapy resulted in migration of blood cells into the brain and improved habituation to a novel environment (Visigalli et al. 2010) . Further studies will need to evaluate the risk of insertional mutagenesis or other adverse events against the efficacy of different vectors for gene therapy.
Although transduction of brain cells after gene therapy did not appear to contribute to the beneficial effect in this study, it has contributed to improvements in other studies. Lentiviral vector administration to newborns resulted in transduction of neurons in the brain, although the effect on behavioral function was not reported (Kobayashi et al. 2005) . Direct injection of AAV8 resulted in expression in brain and improved function in the Morris water maze test (Wolf et al. 2011) , whereas direct injection of AAV into MPS I dogs resulted in expression (Ellinwood et al. 2011; Ciron et al. 2006) , although behavioral function was not assessed. Similarly, although intrathecal injection of AAV resulted in expression in the brain, behavioral function was not evaluated (Watson et al. 2006) . Thus, there are a variety of approaches that have been successfully used to achieve IDUA production in the brain, and some of these studies also documented behavioral improvement.
Implications for future gene therapy studies One of the major concerns of any therapy for MPS I or related diseases is the question of whether or not it will improve behavioral function. Although it has been presumed that enzymes in blood will not cross the blood-brain barrier, a variety of data suggest that some enzymes can reach the brain from blood, albeit the process is somewhat inefficient. This study demonstrates that a gene therapy approach that does not result in expression in the brain can indeed improve behavioral function. It is encouraging that either ERT or systemic gene therapy can improve this important parameter, although the caveat is that very high levels of enzymes in blood, >200 U/ml (71-fold normal), are required to achieve an optimal effect in mice.
